Companies / Czech Republic
Czech Drug Market Contracts
May 2006 | Company Finance AlertPharmaceutical companies in the Czech Republic have seen their revenues fall by CZK1bn (US$45mn) in the first four months of 2006 compared to the same period in the previous year, according to IMS data. The most significant drops were reported by US drugmaker Ivax, local player Zentiva and Swiss firm
Sorry, you must be a subscriber to view this article in full. If you are a subscriber please login.
If you would like to subscribe to Emerging Europe Pharma & Healthcare Insight and gain instant access to this article, please click here to subscribe.
If you would like to take a trial to Emerging Europe Pharma & Healthcare Insight please click on the trial link below.
